Journal of Strength and Conditioning Research, 21(1), pp.259-264
Medical History and Current Health Conditions Doctors review a patients medical history to ensure these medications wont cause harm
Segalen C, Longnus SL, Baetz D, Counillon L, Van Obberghen E (2008) 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside reduces glucose uptake via the inhibition of Na+/H+ exchanger 1 in isolated rat ventricular cardiomyocytes
The GLP-1 shots were a bit intimidating at first, but as days passed, I noticed my appetite becoming more manageable
Feeling Great What would I do without these, theyare a life saver.
What the study found In patients with obesity + HFpEF, semaglutide and tirzepatide showed similar rates of: all-cause death HF hospitalization and the composite outcome (death + HF hospitalization) Key numbers TriNetX federated EHR analysis 3,983 patients total 1:1 propensity-matched: 1,258 vs 1,258 Median follow-up: 24 weeks Primary composite outcome: HR 1.14 (95% CI 0.891.46), p=0.286 My take For cardio-obesity HFpEF care, this is a useful reminder: Drug selection is often aboutthe right patient, the right goal, the right contextnot just which agent gives more weight loss. So in practice, choice may be driven by: tolerability access/cost glycaemic needs comorbidities patient adherence preferences Important caveat: this is retrospective observational EHR data (not a randomized head-to-head trial), with short follow-up